Vanguard Global Advisers
MRNA icon

Vanguard Global Advisers’s Moderna MRNA Stock Holding History

Vanguard Global Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.7M Buy
737,973
+2,011
+0.3% +$104K 0.02% 403
2026
Q1 		$37.4M Buy
+735,962
New +$34.3M 0.02% 466

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Global Advisers's MRNA Position: Q2 2026 in Review

Vanguard Global Advisers increased its Moderna (MRNA) stake by 0.27% in Q2 2026, buying an estimated $104K and bringing the position to 737,973 shares worth $51.7M. The position accounts for 0.02% of the portfolio, ranked #403.

Vanguard Global Advisers first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 730 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Vanguard Global Advisers held 737,973 shares of Moderna worth $51.7M as of Q2 2026.
  • Vanguard Global Advisers bought 2,011 Moderna shares in Q2 2026, an estimated $104K.
  • Moderna made up 0.02% of Vanguard Global Advisers's portfolio in Q2 2026, its #403 holding.
  • Vanguard Global Advisers first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
  • 730 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.